frontier registry the guidant multi-link frontier ™ coronary stent system for the treatment of pts...
TRANSCRIPT
![Page 1: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/1.jpg)
FRONTIER Registry
The Guidant MULTI-LINK FRONTIER™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary Artery Lesions
T. Lefèvre and W. Van der Giessen
On Behalf the FRONTIER Investigators
![Page 2: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/2.jpg)
Objective
• To assess the safety, procedural success, performance and 6 month clinical outcome of bifurcation stenting
• To evaluate angiographic results and 6 month incidence of TSR
• With the use of the Guidant MULTI-LINK FRONTIER Coronary Stent System in patients with de novo or restenotic bifurcation lesions
![Page 3: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/3.jpg)
Study design
• Prospective, non randomized
• 100 patients
• Up to 2 lead in patients per site
• 13 sites - Europe, New Zealand
• Clinical Follow-up
• In-hospital, 30 days and 6 months
• Angiography
• Pre and Post-Procedure
• 6 months
![Page 4: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/4.jpg)
Specially designed dual lumen tipMain Branch (RX)
Side Branch (OTW)
• Designed for preserving side branch access
• Integrated-tip design allows single tip delivery, avoiding wire wrap
• Stent deploys with simultaneous “kissing balloon inflation”
• Wire position is maintained in both branches throughout the procedure
Guidant MUTI-LINK FRONTIER™ Coronary Bifurcation Stent System
![Page 5: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/5.jpg)
Guidant ML FRONTIER™ Coronary Bifurcation Stent System
• Sizes
• Stent length – 18mm (main branch)
• 7 Fr. GC Compatible
Main Branch Balloon 2.5mm 3.0mm 3.5mm 4.0mm
Side Branch Balloon 2.0mm 2.5mm
![Page 6: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/6.jpg)
Two balloons. Two wires. One very special stent.“Provisional T stenting” strategy
Guidant MULTI-LINK FRONTIER™ Deployment Technique
![Page 7: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/7.jpg)
ML FRONTIER™ Deployment Sequence
Guidant MULTI-LINK FRONTIER™ Deployment Technique
Self rotation when out of phase
![Page 8: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/8.jpg)
Primary endpoints
• Incidence of MACE* at 6 months follow-up
* Hierarchical occurrence of Death, Q-wave and non-Q-wave MI, Target Lesion Revascularization (main branch and/or side branch) including PTCA and CABG
![Page 9: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/9.jpg)
Secondary endpoints
• Incidence of MACE at 30 days follow up
• Angiographic binary restenosis rate at 6 months
• Access site complications
• TVF at one and six months follow up
• TVR at six months follow up
• Acute success of stent delivery, deployment, and post dilatation
![Page 10: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/10.jpg)
Key Inclusion Criteria
• Other lesions in different epicardial vessel successfully treated prior to bifurcation procedure
• Native or restenotic (no stent) vessel suitable to receive a 2.5 to 4.0 mm ML FRONTIER Stent
• Target main branch vessel is a major coronary artery with estimated stenosis > 50 and < 100%
• Angle of bifurcation < 75
• Main branch lesion suitable for a total stent length of < 31mm by visual estimate
• Appropriate lesion morphology
![Page 11: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/11.jpg)
Key Exclusion Criteria
• Untreated lesion >50% proximal or distal to target lesion
• Target lesion contains thrombus
• Target lesion is aorto-ostial or left main stem location
• Target lesion or proximal vessel has excessive tortuosity unsuitable for stent delivery
• Heavy or severe calcification
![Page 12: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/12.jpg)
Enrolling Sites (n= 11)
Patients enrolled
Dr. van der Giessen Rotterdam The Netherlands 16
Dr. Ormiston Auckland New Zealand 15
Prof. Schultheiss Berlin Germany 15
Dr. Quillet Tours France 12
Dr.Reimers Mirano Italy 11
Dr. Lefèvre Massy France 10
Dr. Guagliumi Bergamo Italy 9
Dr. Brunel Nantes France 7
Dr. Wijns Aalst Belgium 6
Dr. Büttner Bad Krozingen Germany 2
Dr. Hartmann Lübeck Germany 2
Total 105
![Page 13: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/13.jpg)
FRONTIER Trial Enrollment
![Page 14: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/14.jpg)
Baseline Demographics(Intent-to-treat patient population)
n = 105
Age (years) 62.4(60.3 – 64.5)
Number of men (%) 77.1
Current smoker (%) 27.9
Diabetes requiring treatment (%) 17.1
Hypertension requiring treatment (%) 46.2
Hypercholesterolemia requiring treatment (%) 64.8
Prior MI (%) 36.2
Stable angina: CCS III or IV (%) 14.3
Unstable angina: Braunwald class 1-2 A-B (%) 30.5
Prior CABG (%) 1.0
LAD location (%) 79.1
![Page 15: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/15.jpg)
Baseline QCA Analysis(Intent-to-treat patient population)
Target vessel(n= 103 patients*)
Main branch (%)
Side branch (%)
Moderate to heavy Calcification 29.4 11.7
Thrombus 1.9 0
Pre-procedural TIMI flow
Grade 3 91.3 93.2
ACC / AHA lesion class
A 2.0 26.6
B1 20.8 60.9
B2 77.2 12.5
* Cardialysis, Rotterdam, The Netherlands
![Page 16: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/16.jpg)
Bifurcation Lesion Classification(Intent-to-treat patient population)
Bifurcation angulation < 75 degrees 70.9%
7.9% 24.8%13.9%
36.6% 5.9%
10.9%
Prebranch
Postbranch
Parent Vessel Only
Bifurcation Ostial
Ostial
Prebranch and
A B C
D E F
Cardialysis, Rotterdam, The Netherlands
![Page 17: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/17.jpg)
Device success* 92.2%
Procedural success 93.3%
Use of GPIIb/IIIa inhibitors 26.0%
Additional stent implant
- One only
- More than one
37.1%
6.7%
Reason why additional stent implanted
- To cover target lesion
- Inflow dissection
- Outflow dissection
16.7%
66.7%
16.7%
Stent used
- Diameter (mm)
- Length (mm)
3.03 ± 0.37
12.51 ± 5.57
Procedural data in Main Branch(Intent-to-treat patient population)
* Stent did not cross (8/9), twisted wire (1/9)
![Page 18: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/18.jpg)
Device success* 92.2%
Procedural success 93.3%
Use of GPIIb/IIIa inhibitors 26.0%
Additional elective stent implant as allowed by protocol (n)
37.1%
(39/105)
More than one additional stent (n) **
-To cover target lesion (n)
-Inflow dissection (n)
- Outflow dissection (n)
6.7% (7/105)
1
4
1
Stent used
- Diameter (mm)
- Length (mm)
3.03 ± 0.37
12.51 ± 5.57
Procedural data in Main Branch(Intent-to-treat patient population)
* Stent did not cross (8/9), twisted wire (1/9) ** 1 reason unknown
Caution: Investigational device. Limited by Federal (US) law to investigational use only. Not available for sale
![Page 19: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/19.jpg)
Pre-procedure reference vessel diameter (mm) 2.77 ± 0.51
Lesion length (mm) 12.16 ± 5.83
Pre-dilatation performed (%)
Maximum pre-dilatation balloon size:
- Diameter (mm) - Length (mm) - Balloon pressure (atm)
100
2.68 ± 0.4016.25 ± 3.7710.36 ± 3.13
FRONTIER stent max. deployment pressure (atm) 12.1 ± 2.3
Post stent implant dilatation performed (%)
Maximum post-dilatation balloon size:
- Diameter (mm)- Length (mm)- Balloon pressure (atm)
70.8
3.14 ± 0.4513.43 ± 4.0311.9 ± 3.80
Procedural data in Main Branch(Per protocol patient population)
Cardialysis, Rotterdam, The Netherlands
![Page 20: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/20.jpg)
Lesion length (mm) 4.03 ± 2.71
Pre-procedure reference side branch diameter (mm) 2.10 ± 0.67
Side branch post treatment
- None (%)- Balloon (%)- Stent (%)
19.837.542.7
Stent diameter (mm) 2.64 ± 0.34
Stent length (mm) 9.92 ± 2.81
Maximum balloon diameter (mm) 2.53 ± 0.44
Maximum balloon length (mm) 15.03 ± 4.59
Maximum balloon pressure (atm) 10.15 ± 2.81
Kissing balloon technique performed (%) 79.5
Procedural data in Side Branch(Per protocol patient population)
Cardialysis, Rotterdam, The Netherlands
![Page 21: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/21.jpg)
Main Branch In-stent(n = 96)
Pre-procedure ref. diameter (mm) 2.77 ± 0.51
Pre-procedure DS (%) 60.7 ± 12.2
Pre-procedure MLD (mm) 1.07 ± 0.35
Post-procedure DS (%) 15.1 ± 9.6
Post-procedure MLD (mm) 2.43 ± 0.41
6-month DS (%) 38.8 ± 19.1
6-month MLD (mm) 1.59 ± 0.56
Binary restenosis (>50%) 25.3 %
Acute gain in-stent (mm) 1.36 ± 0.46
Late loss in-stent (mm) 0.84 ± 0.55
QCA Analysis(Per-protocol patient population)
In-stent + 5 mm (n=96)
-
-
-
24.5 ± 9.5
2.04 ± 0.40
40.3 ± 19.29
1.51 ± 0.54
27.6 %
-
-
Cardialysis, Rotterdam, The Netherlands
![Page 22: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/22.jpg)
Side Branch In-segment Total
(n = 96)
Pre-procedure ref. diameter (mm) 2.10 ± 0.67
Pre-procedure DS (%) 39.1 ± 18.1
Pre-procedure MLD (mm) 1.23 ± 0.45
Post-procedure DS (%) 25.1 ± 12.7
Post-procedure MLD (mm) 1.47 ± 0.40
6-month DS (%) 39.4 ± 20.9
6-month MLD (mm) 1.13 ± 0.47
Binary restenosis (>50%) 29.1 %
QCA Analysis(Per-protocol patient population)
Stented
(n = 39)
Ballooned
(n = 36)
Non-treated
(n = 21)
2.32 ± 0.79 2.01 ± 0.53 1.81 ± 0.54
46.7 ± 19.4 37.0 ± 13.9 27.4 ± 15.1
1.17 ± 0.46 1.27 ± 0.44 1.30 ± 0.43
23.8 ± 12.7 27.3 ±11.7 23.6 ± 14.6
1.59 ± 0.42 1.42 ± 0.37 1.30 ± 0.36
44.8 ± 26.2 33.9 ± 14.0 37.6 ± 15.2
1.02 ± 0.56 1.24 ± 0.35 1.19 ± 0.40
36.8 % 18.8 % 31.3 %
![Page 23: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/23.jpg)
MACE(intent-to-treat patient population)
In-Hospital n=105
30 ± 5 days n=105
SAT (%)
Q-wave MI (%)
Non Q-wave MI (%)
0
1.0
1.0
0
1.0
1.0
TLR, CABG or PCI (%) 1.0 1.0
TVR, CABG or PCI (%) 1.0 1.0
Death (%) (Death, MI, TLR) 0 0
MACE (%) 2.9 2.9
Target Vessel Failure (%) (Death, MI, TVR)
2.9 2.9
Hierarchical Ranking
180 ± 10 daysn=105
0
1.9
1.9
13.4
19.1
0
17.1
22.9
![Page 24: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/24.jpg)
Sample calculation (MACE)
Study Alpha Rate n Lower Limit Upper Limit
Finci et al 0.05 37.4% 91 27.4% 48.1%
Yamashita et al 0.05 37.8% 37 22.5% 55.2%
Finci et ali 0.05 62.2% 45 46.5% 76.2%
Yamashita et al 0.05 50.9% 53 36.8% 64.9%
Lefèvre et al 0.05 29.1% 182 17.5% 36.3%
Karvouni et al 0.05 48.4% 62 35.5% 61.4%
Al Suwaidi et al 0.05 26.8% 75 17.1% 38.1%
Al Suwaidi et al 0.05 47.7% 51 32.9% 61.5%
Wt. Avg 29.5% 51.2 %
![Page 25: FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary](https://reader036.vdocument.in/reader036/viewer/2022070412/5697bf7c1a28abf838c843fe/html5/thumbnails/25.jpg)
Conclusion
This new stent specifically designed for treating bifurcation lesions and preserving side branch access can be used with a high procedural success rate.
Compared to previous studies with workhorse stents, the clinical outcome as well as acute angiographic and 6-months results are very encouraging.